KURA compared with MOLN: revenue, margins and what each company keeps, and the suppliers and customers both name

KURAKura Oncology, Inc.

Mkt capRevenueRevenue

MOLNMolecular Partners AG

Mkt capRevenueRevenue

Compare

KURAKura Oncology, Inc.

MOLNMolecular Partners AG

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

KURA: latest quarter is a loss; flow not drawable. MOLN: latest quarter not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only KURA 2

BMYMirati Therapeutics, Inc. (Bristol Myers Squibb)supplier

—Kyowa Kirinunlistedsupplier

Shared 0

No shared counterparties.

Only MOLN 1

—Orano Medunlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

KURAKura Oncology, Inc.

10.27▼−2.79%· post 10.27

Mkt cap$912.7MRevenue$21MQ2 FY26Revenue$67MFY25

MOLNMolecular Partners AG

3.98▲+11.17%· post 3.71

ClosedOct 30 '26

Mkt cap$144.5MRevenue—Revenue—

Compare

ClosedOct 30 '26

KURAKura Oncology, Inc.

MOLNMolecular Partners AG

10.27▼−2.79%post 10.27

Price

3.98▲+11.17%post 3.71

$912.7M

Mkt cap

$144.5M

Q2 FY26$21M

Revenue

—

FY25$67M

Revenue

—

KURA10.27▼−2.79%vsMOLN3.98▲+11.17%ClosedOct 30 '26

Price

rebased to 0%

KURA, solidMOLN, dashed